Literature DB >> 11567810

Treatment of rectal adenocarcinoma with endocavitary and external beam radiotherapy: results for 199 patients with localized tumors.

A Aumock1, E H Birnbaum, J W Fleshman, R D Fry, M A Gambacorta, I J Kodner, R S Malyapa, T E Read, B J Walz, R J Myerson.   

Abstract

PURPOSE: Endocavitary radiation (RT) provides a conservative alternative to proctectomy. Although most suitable for small, mobile lesions, patients with less favorable tumors are often referred if they are poor surgical candidates. Knowing the extent to which radiation can control such tumors can be an important factor in making clinical decisions. METHODS AND MATERIALS: One hundred ninety-nine patients, who received endocavitary RT with or without external beam RT (EBRT) during 1981 through 1995, were followed for disease status for a median of 70 months, including deaths from intercurrent causes. In the early years of the study, 21 patients were treated with endocavitary RT alone, the remainder of the patients received pelvic EBRT (usually 45 Gy in 25 fractions) 5-7 weeks before endocavitary RT.
RESULTS: Overall, 141 patients (71%) had local control with RT alone. Salvage surgery rendered an additional 20 patients disease free, for an ultimate local control rate of 81%. On multivariate analysis for local control (excluding surgical salvage), the most significant factors were mobility to palpation, use of EBRT, and whether pretreatment debulking of all macroscopic disease had been done (generally a piecemeal, nontransmural procedure). Of 77 cases staged by transrectal ultrasonography, the local control rate with RT alone was 100% for uT1 lesions, 85% (90% with no evidence of disease after salvage) for freely mobile uT2 lesions, and 56% (67% with no evidence of disease after salvage) for uT3 lesions and uT2 lesions that were not freely mobile.
CONCLUSIONS: Patients with small mobile tumors that are either uT1 or have only a scar after debulking achieve excellent local control with endocavitary RT. About 15% of mobile uT2 tumors fail RT; therefore, careful follow-up is critical. Small uT3 tumors are appropriate for this treatment only if substantial contraindications to proctectomy are present.

Entities:  

Mesh:

Year:  2001        PMID: 11567810     DOI: 10.1016/s0360-3016(01)01677-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.

Authors:  Robert J Myerson; Benjamin Tan; Steven Hunt; Jeffrey Olsen; Elisa Birnbaum; James Fleshman; Feng Gao; Lannis Hall; Ira Kodner; A Craig Lockhart; Matthew Mutch; Michael Naughton; Joel Picus; Caron Rigden; Bashar Safar; Steven Sorscher; Rama Suresh; Andrea Wang-Gillam; Parag Parikh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-15       Impact factor: 7.038

2.  HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice.

Authors:  Yi Chen; Xiao-Lin Wang; Zhi-Ping Yan; Jie-Min Cheng; Jian-Hua Wang; Gao-Quan Gong; Sheng Qian; Jian-Jun Luo; Qing-Xin Liu
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

Review 3.  Management of locally advanced rectal cancer in the elderly: a critical review and algorithm.

Authors:  Lara Hathout; Nell Maloney-Patel; Usha Malhotra; Shang-Jui Wang; Sita Chokhavatia; Ishita Dalal; Elizabeth Poplin; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2018-04

4.  Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach.

Authors:  Maximilian Fleischmann; Markus Diefenhardt; Martin Trommel; Christian Scherf; Ulla Ramm; Georgios Chatzikonstantinou; Emmanouil Fokas; Claus Rödel; Nikolaos Tselis
Journal:  Strahlenther Onkol       Date:  2022-04-20       Impact factor: 4.033

5.  Efficacy and Safety of Low-Dose-Rate Endorectal Brachytherapy as a Boost to Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Distal Rectal Cancer: A Phase-II Clinical Trial.

Authors:  Shapour Omidvari; Shadi Zohourinia; Mansour Ansari; Leila Ghahramani; Mohammad Zare-Bandamiri; Ahmad Mosalaei; Niloofar Ahmadloo; Saeedeh Pourahmad; Hamid Nasrolahi; Sayed Hasan Hamedi; Mohammad Mohammadianpanah
Journal:  Ann Coloproctol       Date:  2015-08-31

Review 6.  Ablative therapies for colorectal polyps and malignancy.

Authors:  Jacqueline Oxenberg; Steven N Hochwald; Steven Nurkin
Journal:  Biomed Res Int       Date:  2014-06-26       Impact factor: 3.411

Review 7.  Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer.

Authors:  Valentina Lancellotta; György Kovács; Luca Tagliaferri; Elisabetta Perrucci; Giuseppe Colloca; Vincenzo Valentini; Cynthia Aristei
Journal:  Biomed Res Int       Date:  2018-01-21       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.